Conagra Brands, Inc.
CAG
$14.57
+3.41%
Conagra Brands is a packaged food manufacturer whose portfolio spans frozen meals (Marie Callender's, Healthy Choice, Banquet, Birds Eye), snacks (Slim Jim, Orville Redenbacher's), and shelf-stable staples (Hunt's, Duncan Hines, Vlasic, Reddi-wip), sold primarily through U.S. retail channels with roughly 91% of fiscal 2025 revenue domestic and only about 9% each from international and foodservice. It is a mature, brand-owning staple of the Consumer Defensive sector rather than a growth disruptor, competing on shelf space, brand equity, and cost discipline against peers like General Mills, Campbell's, and private-label offerings. The current investor narrative is dominated by distress and turnaround debate: an unexpected CEO replacement, a 52-week-low print following weak earnings and guidance, a shockingly high dividend yield that some view as a signal of financial strain and cut risk, and a portfolio widely criticized as outdated against shifting consumer preferences. Sentiment is further complicated by a large impairment-driven loss in fiscal Q4 2026 that has distorted trailing profitability metrics, leaving investors to weigh deep value and a fat dividend against execution risk and balance-sheet leverage.…
CAG
Conagra Brands, Inc.
$14.57
Related headlines
Investment Opinion: Should I buy CAG Today?
Rating: Hold. The core thesis is that CAG offers deep value at 0.56x sales and 0.99x book with a 10.7% dividend yield, but the risk of a dividend cut and lack of near-term catalysts justify a wait-and-see approach. The analyst consensus rating of hold (mean 3.44) and average target of $13.74 (7.5% below the current price) reinforce this cautious stance.
Supporting evidence: The forward PE of 9.92x is well below the market average, and the PS ratio of 0.56x is a fraction of its historical 5.32x, suggesting deep pessimism is priced in. However, revenue is declining (-1.39% YoY), gross margin has compressed to 23.83%, and free cash flow in the latest quarter was negative, casting doubt on the dividend's sustainability. The 10.66% yield is attractive but likely reflects a high probability of a cut, and the balance sheet carries a debt-to-equity of 1.14 with a current ratio of 0.90.
Risks and conditions: The biggest risks are a dividend cut, continued revenue erosion, and execution missteps by the new CEO. The rating would upgrade to Buy if the company demonstrates stable revenue and free cash flow coverage of the dividend for two consecutive quarters, or if the stock falls below $12.50 (near the 52-week low) with signs of stabilization. It would downgrade to Sell if the dividend is cut or if revenue declines accelerate beyond -3%. Valuation verdict: The stock is deeply undervalued relative to its history and peers, but the discount is justified by fundamental deterioration; a turnaround is needed to unlock value.
Sign up to view all
CAG 12-Month Price Forecast
The risk/reward is balanced but skewed to the downside in the near term due to dividend sustainability concerns and lack of catalysts. The deep-value multiples provide a margin of safety, but the stock needs a clear operational turnaround to re-rate. We would upgrade to bullish if the new CEO announces a credible plan and free cash flow covers the dividend for two quarters, and downgrade to bearish if the dividend is cut or revenue declines accelerate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Conagra Brands, Inc.'s 12-month outlook, with a consensus price target around $13.74 and implied upside of -5.7% versus the current price.
Average Target
$13.74
0 analysts
Implied Upside
-5.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$11 - $16
Analyst target range
Coverage is reasonably broad with 15 analysts, but the consensus is decidedly cautious: the recommendation is "hold" with a mean rating of 3.44 on what appears to be a 1-to-5 scale (where 5 is sell), and the average target price of $13.74 sits below the current $14.86 price — implying roughly -7.5% downside to consensus. That is a bearish signal: the stock has rallied past where the average analyst thinks it belongs, and the distribution skews toward Hold/Neutral/Sector Perform names (Deutsche Bank, UBS, RBC, JP Morgan, Evercore) with only Barclays carrying an Overweight. The consensus is therefore neutral-to-bearish, reflecting skepticism that the recent bounce is sustainable. The target range of $11.00 to $16.00 is moderately wide relative to the $13.74 midpoint, signaling meaningful uncertainty: the $16.00 high assumes successful execution of the turnaround, margin recovery, and possibly multiple re-rating toward book value, while the $11.00 low discounts continued volume declines, margin compression, and a dividend cut or balance-sheet stress. Institutional ratings show no recent upgrades — actions since June 2026 are all reiterations of Hold, Neutral, Sector Perform, or In Line — which suggests analysts are in wait-and-see mode pending clarity on the new CEO's strategy and the next earnings print. With the average target below the current price and no upgrade momentum, the analyst community is effectively signaling that the risk/reward is balanced at best, and the wide $5.00 spread between high and low targets confirms low conviction in either direction.
Bulls vs Bears: CAG Investment Factors
The bear case currently has stronger evidence, driven by declining revenue, a potentially unsustainable dividend, and a consensus analyst target below the current price. The bull case rests on deep-value multiples (0.56x sales, 0.99x book) and a forward PE of 9.9x that already discounts significant pessimism, but without a clear catalyst for operational improvement, the stock remains a value trap. The single most important tension is whether the new CEO can stabilize the frozen franchise and restore cash flow to cover the dividend; a dividend cut would likely validate the bear thesis, while successful margin recovery could trigger a re-rating. Near-term momentum is positive, but the long-term trend and fundamentals remain negative, suggesting caution until tangible progress is demonstrated.
Bullish
- Deep value on sales and book: At $14.86, CAG trades at just 0.56x sales and 0.99x book, versus its own historical PS of 5.32x in Q1 2025 and 2.18x at fiscal year-end 2026. The price-to-book of 0.99x is near the bottom of its multi-year band, implying the market is pricing in significant structural deterioration that may already be reflected in the stock.
- Forward PE of 9.9x on normalized EPS: Consensus EPS of $1.57 for the next fiscal year implies a forward PE of 9.92x, a steep discount to the broader market and typical packaged-food peers. This multiple suggests the market expects earnings to normalize once the $2.93 billion impairment charge rolls off, and any positive surprise could drive multiple expansion.
- Dividend yield of 10.7% is extreme: The stock yields 10.66%, far above the sector average and its own history, which could attract income investors if the dividend is maintained. However, the negative payout ratio of -0.35 and recent free cash flow shortfall raise questions about sustainability, making this a high-risk, high-reward proposition.
- Recent momentum diverging from annual trend: Despite a -19.55% one-year decline, the stock is up 4.87% over six months and 0.54% over one month, with a relative strength of +1.56 versus SPY in the past month. The sharp 7.3% single-day jump on October 22 on elevated volume of 9.4 million shares suggests capitulation-style buying and potential for a mean-reversion rally.
Bearish
- Revenue declining and guidance weak: Most recent quarterly revenue fell 1.39% year over year to $2.596 billion, continuing a multi-quarter erosion from $2.979 billion in Q2 2026. Consensus estimates of $10.95 billion imply further low-single-digit contraction, and the core frozen franchise is under pressure from shifting consumer preferences.
- Dividend appears uncovered by cash flow: In the latest quarter, operating cash flow was -$4.2 million and free cash flow was -$127.9 million, while dividends paid were $167.5 million. The negative payout ratio of -0.35 and 10.66% yield signal the market is already discounting a dividend cut, which would likely trigger further selling.
- Balance sheet leverage and liquidity concerns: Debt-to-equity stands at 1.14 and the current ratio is a thin 0.90, indicating limited short-term liquidity. The company relied on $434.8 million of other financing activities to fund the shortfall, highlighting dependence on external capital and potential refinancing risk in a higher-rate environment.
- Analyst consensus hold with downside to target: The average analyst target of $13.74 is 7.5% below the current price, and the consensus recommendation is hold with a mean rating of 3.44 (where 5 is sell). No recent upgrades and a wide target range of $11-$16 reflect low conviction and skepticism about the sustainability of the recent bounce.
CAG Technical Analysis
CAG is in a sustained downtrend that has only recently begun to stabilize, with a 1-year price change of -19.55% versus a +13.13% gain for SPY, a relative-strength gap of -32.68 percentage points. At the current price of $14.86, the stock sits roughly 11.5% above its 52-week low of $12.53 and about 26.9% below its 52-week high of $20.32, placing it at approximately 37% of its 52-week range — closer to the floor than the ceiling, which historically signals either a value opportunity or a falling knife rather than momentum. The -14.10% YTD decline confirms the longer-term trend remains negative despite the recent bounce. Short-term momentum, however, has turned constructive and is diverging from the annual trend: the stock is up 0.54% over 1 month, 0.61% over 3 months, and 4.87% over 6 months, with a relative-strength reading of +1.56 versus SPY over the past month even as SPY fell 1.02%. This positive 1-month/3-month momentum against a deeply negative 1-year trend is characteristic of mean-reversion off a washed-out base, and the sharp single-day move from $14.04 on October 21 to $15.07 on October 22 (+7.3%) on elevated volume of roughly 9.4 million shares suggests capitulation-style buying rather than a durable trend reversal. Key technical levels are clear: support rests at the 52-week low of $12.53, and a breakdown below that would signal a resumption of the primary downtrend and likely force further dividend and balance-sheet reassessment; resistance sits at the $20.32 high, with intermediate overhead near the $16.00–$16.67 area where the August rally stalled. Beta is reported as 0.0, which is not a usable volatility measure here, but the -37.16% max drawdown and the 7%+ single-session swings indicate realized volatility well above what a defensive staples name would typically exhibit, warranting smaller position sizing and wider stops.
Beta
0.00
0.00x market volatility
Max Drawdown
-37.2%
Largest decline past year
52-Week Range
$13-$20
Price range past year
Annual Return
-16.4%
Cumulative gain past year
| Period | CAG Return | S&P 500 |
|---|---|---|
| 1m | +8.4% | -0.9% |
| 3m | +0.4% | +1.2% |
| 6m | +3.6% | +4.9% |
| 1y | -16.4% | +11.2% |
| ytd | -15.8% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAG Fundamental Analysis
Revenue is stagnating to slightly declining: the most recent quarter (ended 2026-08-30) posted $2.596 billion, down 1.39% year over year, and the multi-quarter trend shows sequential erosion from $2.979 billion (Q2 2026) to $2.788 billion (Q3) to $2.882 billion (Q4) to $2.596 billion (Q1 2027), with the prior-year comparable quarter at $2.633 billion. Segment data shows Grocery & Snacks at $2.234 billion and Refrigerated & Frozen at $2.257 billion as the two dominant pillars, with International at $457 million and Foodservice at $567 million — meaning the frozen franchise, the company's core identity, is the swing factor for any recovery. Consensus revenue estimates of roughly $10.95 billion imply continued low-single-digit contraction, so the investment case currently rests on stabilization and margin repair rather than top-line growth. Profitability is bifurcated: the latest quarter was solidly profitable with net income of $174.3 million, a 6.71% net margin, and a 23.83% gross margin, but the fiscal Q4 2026 reported a catastrophic net loss of $1.617 billion (EPS -$3.37) driven by a $2.93 billion other-expense line and a -$2.627 billion operating loss, which is almost certainly a non-cash goodwill/intangible impairment rather than an operating collapse. Gross margin has compressed modestly over the year, from 24.33% in Q1 2026 to 23.83% in the latest quarter, and the trailing net margin of -16.99% and operating margin of -14.43% are artifacts of that impairment, not the underlying run-rate. The key takeaway is that core operating margins of roughly 10% remain intact, but the impairment confirms that management's own view of the frozen portfolio's carrying value has deteriorated materially. Balance-sheet and cash-flow health is the real pressure point: debt-to-equity stands at 1.14, the current ratio is a thin 0.90, and the latest quarter produced negative operating cash flow of -$4.2 million and negative free cash flow of -$127.9 million against $123.7 million of capex and $167.5 million of dividends paid — meaning the dividend was not covered by internal cash generation in the quarter. TTM free cash flow of $877 million and a 4.48x price-to-cash-flow ratio show the business can still throw off cash, but ROE of -30.14% and ROA of 4.05% underscore how the impairment has wrecked reported returns, and the reliance on $434.8 million of other financing activities to fund the shortfall highlights dependence on external capital.
Quarterly Revenue
$2.6B
2026-08
Revenue YoY Growth
-1.4%
YoY Comparison
Gross Margin
23.8%
Latest Quarter
Free Cash Flow
$877000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAG Overvalued?
Because trailing net income is negative (EPS of -$0.305 and a trailing PE of -3.28x), the PE ratio is not meaningful and I am leading with the price-to-sales ratio of 0.56x and the forward PE of 9.92x as the primary valuation anchors. The gap between the unusable trailing PE and the 9.92x forward multiple — against consensus EPS of $1.57 — implies the market expects a sharp earnings normalization once impairment charges roll off, and the 0.56x PS ratio is exceptionally low for a branded staples company, pricing in significant skepticism about the durability of the franchise. On peer comparison, a 0.56x PS and 0.99x price-to-book sit well below the 1.5x–2.0x book multiples CAG itself commanded in 2023–2024, and the 1.29x EV/sales is modest for a packaged-foods peer group that typically trades at 1.5x–2.5x sales; the discount is arguably justified by negative 1.4% revenue growth, a 23.8% gross margin that trails historical levels, and the balance-sheet leverage. Historical context reinforces the de-rating: CAG's PS ratio has collapsed from 5.32x in Q1 2025 and 4.11x in Q2 2025 to 2.18x at fiscal year-end 2026 and 0.56x on the current market-cap basis, while price-to-book has fallen from 1.71x to 0.99x — near the bottom of its multi-year band. That places the stock at a deep-value extreme, which either represents a genuine margin-of-safety opportunity or reflects the market pricing in structural deterioration and potential dividend reduction; the negative payout ratio of -0.35 and a 10.66% dividend yield signal the market is already discounting a cut.
PE
-3.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated. Revenue is contracting (-1.39% YoY) and the latest quarter saw negative free cash flow of -$127.9 million, insufficient to cover $167.5 million in dividends, raising the specter of a dividend cut. Debt-to-equity of 1.14 and a current ratio of 0.90 indicate a leveraged balance sheet with limited liquidity, while the $2.93 billion impairment in Q4 2026 underscores the risk of further write-downs if the frozen portfolio continues to underperform. Margin pressure is evident with gross margin at 23.83%, down from 24.33% a year earlier, and operating margin (excluding impairment) around 10%, leaving little room for error.
Market and competitive risks include valuation compression and sector headwinds. The stock's PS ratio has collapsed from 5.32x to 0.56x, reflecting a massive de-rating that could continue if earnings fail to recover. Competition from private-label brands and peers like General Mills and Campbell's is intensifying, and consumer preferences are shifting away from processed frozen foods. The reported beta of 0.0 is not meaningful, but the -37.16% max drawdown and 7%+ single-day swings indicate realized volatility well above typical defensive staples, suggesting sensitivity to news flow and sentiment. Recent news highlights the unexpected CEO replacement and 52-week low as bearish signals, with no clear turnaround catalyst yet.
Worst-case scenario: A dividend cut combined with continued revenue declines and a failed turnaround could drive the stock to its 52-week low of $12.53, representing a 15.7% decline from the current price. If the new CEO announces a strategic reset that includes further impairments or a rights offering, the stock could test the analyst low target of $11.00, a 26% downside. Historical max drawdown of -37.16% implies a potential drop to around $9.34 in a severe market dislocation, though that is less likely absent a broader crisis. Investors should be prepared for significant volatility and potential capital loss.
FAQ
The biggest risk is a dividend cut, given the negative payout ratio and free cash flow shortfall. Revenue is declining, and the frozen food portfolio is losing relevance with consumers. The balance sheet carries a debt-to-equity of 1.14 and a current ratio of 0.90, limiting financial flexibility. Execution risk is high with the new CEO, and further impairments could occur if the portfolio's value continues to deteriorate. Additionally, the stock has exhibited high volatility with a -37.16% max drawdown, so position sizing is crucial.
Our 12-month forecast has a base case (50% probability) of $13.00-$14.50, assuming revenue declines stabilize and the dividend is maintained. The bull case (25%) targets $16.00-$18.00 if the new CEO successfully executes a turnaround and margins recover. The bear case (25%) targets $11.00-$12.50 if the dividend is cut and revenue declines accelerate. The most likely scenario is the base case, where the stock trades around the analyst average target of $13.74, reflecting a fairly valued but unexciting outlook.
CAG appears deeply undervalued on traditional metrics: PS of 0.56x, PB of 0.99x, and forward PE of 9.92x. The PS ratio has collapsed from 5.32x in early 2025 to 0.56x, reflecting a massive de-rating. However, the discount is justified by negative revenue growth, margin compression, and balance sheet leverage. The market is pricing in a high probability of a dividend cut and continued operational challenges. Relative to its own history, the stock is at the bottom of its valuation range, but without a turnaround catalyst, it may remain cheap for a reason.
CAG is a high-risk, high-reward deep-value play. The stock trades at 0.56x sales and 0.99x book, with a forward PE of 9.92x, which is cheap relative to history and peers. However, revenue is declining (-1.39% YoY), free cash flow was negative in the latest quarter, and the 10.66% dividend yield may be unsustainable. The analyst consensus is hold with an average target of $13.74, 7.5% below the current price. For value investors with a long horizon and tolerance for volatility, it could be a contrarian buy, but only if they believe the new CEO can turn around the frozen franchise. Otherwise, wait for signs of stabilization.
CAG is more suitable for long-term value investors with a horizon of at least 2-3 years, as the turnaround will take time to materialize. The high dividend yield (10.66%) could provide income, but the risk of a cut means investors should not rely on it. Short-term trading is risky due to high volatility (7%+ daily swings) and low analyst conviction. A minimum holding period of 2 years is recommended to allow for operational improvements and potential multiple re-rating. The stock is not suitable for growth-oriented investors.